Research programme: HN-1 peptide anticancer therapeutics - Tapestry PharmaceuticalsAlternative Names: HN-1 peptide delivery; HN-1 Taxane A proprietary synthetic peptide/paclitaxel conjugate
Latest Information Update: 19 Nov 2007
At a glance
- Originator M. D. Anderson Cancer Center; Tapestry Pharmaceuticals
- Class Taxanes
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Squamous cell cancer
Most Recent Events
- 07 May 2004 NaPro Biotherapeutics is now called Tapestry Pharmaceuticals
- 03 Apr 2003 Preclinical trials in Squamous cell cancer in USA (unspecified route)